Immunotech Biopharm Ltd

Immunotech Biopharm Ltd is a cellular immunotherapy biopharmaceutical company focused on the research, development, and commercialization of T cell immunotherapy products for cancer treatment in the People's Republic of China. Its core product, EAL, is a multi-target cellular immunotherapy that has completed Phase III clinical trials for the prevention of postsurgical recurrence of liver cancer. The company also develops CAR-T-19 injection for B-cell acute lymphoblastic leukaemia (Phase II/III), 6B11-OCIK injection for ovarian cancer (Phase I), RC19D2 for relapsed and refractory diffuse large B-cell lymphoma (Phase I), and TCR-T cell series products for solid tumors. In addition, it develops pre-clinical products including aT19 and VAC-aT19 for hematologic malignancies, YT003 and YT008 for post-transplantation infections, and YT007 for solid tumors. Founded in 2006, the company is headquartered in Beijing, the People's Republic of China.